Novovax has finished a phase 3 trial of its COVID-19 vaccine candidate that included 30,000 participants in the United States and Mexico. The data is now with the FDA for review and possible approval. Results from a phase 3 trial in the UK had been encouraging, but American regulators require a phase 3 trial conducted in the U.S. before approval.